Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Federal support could get the troubled chip maker over some hurdles, but risks great harm to the U.S. tech sector. The AI cloud operator has soared since its IPO, but a coming flood of shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback